Anne P. O’Dea

Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer

Noor Lad, Sarah Blocker, Taylor Monson, Dennis W. Grauer et autres

us (code pays fourni par la source)

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

José Á. García-Sáenz, Sara López‐Tarruella, Hugo Alejandro Fuentes, Qamar J. Khan et autres

PURPOSE: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of …

us (code pays fourni par la source)

Artificial intelligence (AI) as a decision support tool for practicing oncologists.

Mohammad Jahanzeb, Kayla J. Haines, David Ross Camidge, Walter John Curran et autres

557 Background: Second opinions and multidisciplinary reviews (MDR) are known to alter the management of cancer patients in a substantial percentage of cases, yet these resources are not universally available. We previously presented more than 400 anonymized complex cancer scenarios (cases) to …

us (code pays fourni par la source)

Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer

Shane Richard Stecklein, Roberto Salgado, Julia R. White, Bruce F. Kimler et autres

PURPOSE: The radiosensitivity index (RSI) is a validated gene expression-based biomarker that can predict intrinsic radiosensitivity and has been shown to be associated with local control in patients with triple-negative breast cancer (TNBC) treated with upfront surgery. Currently, most patients with TNBC …

us, au (code pays fourni par la source)

Abstract P4-01-22: Serum Thymidine Kinase as a Biomarker for Response Beyond Progression in First-line CDK 4/6 Inhibitors: Insights from the Randomized Phase II MAINTAIN Trial

Ruth Lauren Sacks, Codruta C. Chiuzan, Melissa Kate Accordino, Elizabeth A. Sakach et autres

Abstract Background: There are multiple therapeutic strategies for patients (pts) with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) following progression on a first-line cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and endocrine therapy (ET). There is an unmet need for …

Abstract P3-11-17: A Randomized Phase II Trial of Neo-adjuvant Chemotherapy with Metformin or Placebo for HER-2 Positive Operable Breast Cancer (The HERMET Trial)

Maire Okoniewski, Cory R. Bivona, Colleen Bohnenkamp, Francisco Martínez Díaz et autres

Abstract Background: Human epidermal growth factor receptor 2 (HER-2) is overexpressed in 15-20% of breast cancer (BC). Pathologic complete response (pCR) after HER-2 directed chemotherapy is an important surrogate marker for survival in HER-2+ operable BC. Patients with diabetes who receive metformin …

Abstract P1-10-10: Outcomes of Abemaciclib Dose Escalation Strategy in High-Risk Early Breast Cancer

Priyanka Sharma, Qamar Khan, Lauren Elizabeth Nye, Anne P. O’Dea

Abstract Background: Abemaciclib is recommended as adjuvant therapy in node-positive, HR+, HER2-, high-risk early breast cancer, based on improved invasive disease-free survival (iDFS) in the monarchE trial. However, there are challenges with tolerability of standard dose abemaciclib. In monarchE, 16.6% discontinued abemaciclib …

Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC).

Priyanka Sharma, Jaimie Heldstab, Rachel Yoder, Joshua M. Staley et autres

1094 Background: Sacituzumab govitecan (TROP2-directed antibody drug conjugate, ADC) is effective in treatment of pretreated HER2-negative MBC. PI3K is the most frequently altered pathway in breast cancer. This phase I trial investigated the combination of SG plus alpelisib (oral α-specific PI3K inhibitor) …

us (code pays fourni par la source)

Standard-dose vs fixed-dose capecitabine in patients with advanced gastrointestinal and metastatic breast cancer.

Nanuli Gvazava, Qamar J. Khan, Lauren August Clark, Joaquina Celebre Baranda et autres

1091 Background: Capecitabine at the FDA-approved standard dose (SD) of 1250 mg/m² twice daily for 14 days with a 7-day break, has significant toxicities. We conducted a randomized trial comparing SD and fixed dose (FD) Capecitabine 1500 mg twice daily, 7 days …

us (code pays fourni par la source)

Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial

Qamar J. Khan, Colleen Bohnenkamp, Taylor Monson, Milind A. Phadnis et autres

PURPOSE In metastatic breast cancer (MBC), oral capecitabine prescribed at the US Food and Drug Administration (FDA)–approved dose of 1,250 mg/m 2 twice daily, 14 days on, 7 days off, is associated with poor tolerance. Mathematical models suggest that a fixed-dose (FD), …

us (code pays fourni par la source)

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Mariana Chávez‐MacGregor, Jieling Miao, Lajos Pusztai, Matthew Philip Goetz et autres

PURPOSE Phosphatidylinositol 3-kinase/AKT-serine threonine kinase/mammalian target of rapamycin (mTOR) pathway abnormalities contribute to endocrine resistance. Everolimus, an mTOR inhibitor, improved progression-free survival in hormone receptor–positive metastatic breast cancer (BC) when combined with endocrine therapy (ET). In this phase III randomized, placebo-controlled trial, …

us (code pays fourni par la source)

KANSURVIVE: Testing a telementoring model for improving cancer survivorship care in rural practice.

Jennifer R. Klemp, Catherine J. Knight, Edward F. Ellerbeck, Christie A. Befort et autres

e13791 Background: Cancer survivors require long-term, coordinated care to address the physical, emotional, and psychosocial effects of cancer and its treatment. KanSurvive, a single arm feasibility trial, evaluated the effectiveness of the KanSurvive ECHO intervention combined with practice facilitation (PF) to promote …

us (code pays fourni par la source)